A first-in-man phase I and pharmacokinetic study on CHR-2797 (tosedostat),an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4978-4985

  Reid, Alison H M ^a,b   Protheroe, Andrew ^c   Attard, Gerhardt ^a,b   Hayward, Nikki ^c   Vidal, Laura ^a   Spicer, James ^a   Shaw, Heather M ^a   Bone, Elizabeth A ^d   Carter, Joanne ^d   Hooftman, Leon ^d   Harris, Adrian ^c   De Bono, Johann S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d Chroma Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BESTATIN; CHR 2797; CHR 79888; ENZYME INHIBITOR; TOSEDOSTAT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHROCYTE; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPONATREMIA; INSOMNIA; KIDNEY CARCINOMA; LOWER RESPIRATORY TRACT INFECTION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR XENOGRAFT; VISUAL DISORDER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMINOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GLYCINE; HALF-LIFE; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 68049128092     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0306     Document Type: Article

References (21)

1. Krige D, Needham LA, Bawden LJ, et al. CHR- 2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 2008;68:6669-6679
2. Hashida H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002;122:376-386 (Pubitemid 34116989)
3. DuBois RN. Leukotriene A4 signaling, inflammation, and cancer. J Natl Cancer Inst 2003;95: 1028-1029
4. Chen X, Li N, Wang S, et al. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Natl Cancer Inst 2003;95:1053-1061 (Pubitemid 36950109)
5. Wang S, Ju J, Wang P, et al. Overexpression of LTA4H in colon cancer of humans and animal models. Proc Am Assoc Cancer Res 2004;45.
6. Saric T, Graef CI, Goldberg AL. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 2004;279: 46723-46732 (Pubitemid 39518320)
7. Hutson RG, Warskulat U, Haussinger D, et al. An example of nutrient control of gene expression: amino acid-dependent regulation of asparagine synthetase. Clin Nutr 1996;15:327-331 (Pubitemid 27042549)
8. Jousse C, Bruhat A, Harding HP, et al. Amino acid limitation regulates CHOP expression through a specific pathway independent of the unfolded protein response. FEBSLett 1999;448:211-216 (Pubitemid 29168490)
9. Hileman EO, Liu J, Albitar M, et al. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004;53:209-219 (Pubitemid 38293718)
10. Scott GS, Bolton C. L-arginine modifies free radical production and the development of experimental allergic encephalomyelitis. Inflamm Res 2000;49:720-726 (Pubitemid 32097089)
11. Wheatley DN, Scott L, Lamb J, et al. Single amino acid (arginine) restriction: growth and death of cultured HeLa and human diploid fibroblasts. Cell Physiol Biochem 2000;10:37-55. (Pubitemid 30219714)
12. Ichinose Y, Genka K, Koike T, et al. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst 2003;95:605-610 (Pubitemid 36553507)
13. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-1147 (Pubitemid 27337928)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al, European Organization for Research and Treatment of CancerNational Cancer Institute of the United StatesNational Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
15. Lowenberg B, Davies F, Müller-Tidow C, et al. A multicenter phase II study of the aminopeptidase inhibitor, CHR-2797, in the treatment of elderly and/or previously treated patients with acute myeloid leukemia. Blood 2008;112.
16. Davies F, Ossenkoppele G, Zachee P, et al. A phase I Study of CHR-2797, an orally active aminopeptidase inhibitor in elderly and/or treatment refractory patients with acute myeloid leukemia or multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2007;110.
17. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic- uremic syndrome. N Engl J Med 1998;339:1578-1584 (Pubitemid 28536132)
18. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594 (Pubitemid 28536133)
19. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001;14:437-454 (Pubitemid 32677088)
20. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100:710-713 (Pubitemid 34761143)
21. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059-41063 (Pubitemid 33671145)